CompletedPhase 3NCT00678327
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Peter Johnson, MDUniversity Hospital Southampton NHS Foundation Trust
- Intervention
- bleomycin sulfate(biological)
- Enrollment
- 1202 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2008 – 2024
Study locations (1)
- Southampton General Hospital, Southampton, England, United Kingdom
Collaborators
Cancer Research UK · Cancer Research UK & UCL Cancer Trials Centre
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00678327 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →